RU2019137004A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019137004A3 RU2019137004A3 RU2019137004A RU2019137004A RU2019137004A3 RU 2019137004 A3 RU2019137004 A3 RU 2019137004A3 RU 2019137004 A RU2019137004 A RU 2019137004A RU 2019137004 A RU2019137004 A RU 2019137004A RU 2019137004 A3 RU2019137004 A3 RU 2019137004A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501696P | 2017-05-04 | 2017-05-04 | |
| US62/501,696 | 2017-05-04 | ||
| USPCT/US2017/048748 | 2017-08-25 | ||
| PCT/US2017/048748 WO2018039642A1 (en) | 2016-08-26 | 2017-08-25 | Compositions and methods thereof |
| TW106129169A TW201815387A (zh) | 2016-08-26 | 2017-08-28 | 組成物及其方法 |
| TW106129169 | 2017-08-28 | ||
| US201862634162P | 2018-02-22 | 2018-02-22 | |
| US62/634,162 | 2018-02-22 | ||
| US201862635554P | 2018-02-27 | 2018-02-27 | |
| US201862636099P | 2018-02-27 | 2018-02-27 | |
| US62/636,099 | 2018-02-27 | ||
| US62/635,554 | 2018-02-27 | ||
| US201862636171P | 2018-02-28 | 2018-02-28 | |
| US62/636,171 | 2018-02-28 | ||
| PCT/US2018/030978 WO2018204713A1 (en) | 2017-05-04 | 2018-05-03 | Targeted drug rescue with novel compositions, combinations, and methods thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| RU2019137004A3 true RU2019137004A3 (ru) | 2021-06-04 |
| RU2019137004A RU2019137004A (ru) | 2021-06-04 |
| RU2760558C2 RU2760558C2 (ru) | 2021-11-29 |
| RU2760558C9 RU2760558C9 (ru) | 2022-02-22 |
Family
ID=65431106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019137004A RU2760558C9 (ru) | 2017-05-04 | 2018-05-03 | Целевой лекарственный препарат и новые композиции, комбинации на его основе и способы их применения |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3618819A4 (ru) |
| JP (2) | JP2020518617A (ru) |
| KR (2) | KR102444803B1 (ru) |
| CN (1) | CN110831584B (ru) |
| AU (2) | AU2018261654A1 (ru) |
| BR (1) | BR112019022902A2 (ru) |
| CA (2) | CA3062452C (ru) |
| IL (1) | IL270326B2 (ru) |
| MA (1) | MA49464A (ru) |
| RU (1) | RU2760558C9 (ru) |
| TW (1) | TWI787260B (ru) |
| WO (1) | WO2018204713A1 (ru) |
| ZA (1) | ZA201908006B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3941469A4 (en) * | 2019-03-18 | 2022-05-18 | Avanir Pharmaceuticals, Inc. | METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTTERATED DEXTROMETHORPHANE AND QUINIDINE |
| IL297492A (en) | 2020-05-19 | 2022-12-01 | Cybin Irl Ltd | Denatured Tryptamine Derivatives and Methods of Use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4241065A (en) * | 1979-07-02 | 1980-12-23 | E. I. Du Pont De Nemours And Company | Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both |
| US4950658A (en) * | 1988-12-06 | 1990-08-21 | Board Of Trustees Of Southern Illinois Univ. | Method of medical treatment of Alzheimer's disease |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| EP2162135A4 (en) * | 2007-05-21 | 2012-02-22 | Reviva Pharmaceuticals Inc | COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS |
| US8017623B2 (en) * | 2008-07-03 | 2011-09-13 | Trinity Laboratories, Inc. | Dextromethorphan hydrochloride |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| JP6495191B2 (ja) * | 2013-03-07 | 2019-04-03 | マインドラブ・エルエルシー | 鎮痛薬の組合せおよびその使用 |
| CA2907357A1 (en) * | 2013-03-15 | 2014-09-18 | Kinemed, Inc. | Biomarkers |
| AU2017315947B2 (en) * | 2016-08-26 | 2022-12-01 | Exciva GmbH | Compositions and methods thereof |
-
2018
- 2018-05-03 KR KR1020217033764A patent/KR102444803B1/ko active IP Right Grant
- 2018-05-03 RU RU2019137004A patent/RU2760558C9/ru active
- 2018-05-03 CN CN201880037396.3A patent/CN110831584B/zh active Active
- 2018-05-03 CA CA3062452A patent/CA3062452C/en active Active
- 2018-05-03 CA CA3138116A patent/CA3138116A1/en active Pending
- 2018-05-03 KR KR1020197035796A patent/KR20200062078A/ko not_active Application Discontinuation
- 2018-05-03 WO PCT/US2018/030978 patent/WO2018204713A1/en active Application Filing
- 2018-05-03 AU AU2018261654A patent/AU2018261654A1/en not_active Abandoned
- 2018-05-03 MA MA049464A patent/MA49464A/fr unknown
- 2018-05-03 JP JP2019560216A patent/JP2020518617A/ja active Pending
- 2018-05-03 BR BR112019022902A patent/BR112019022902A2/pt active Search and Examination
- 2018-05-03 EP EP18794381.6A patent/EP3618819A4/en active Pending
- 2018-05-04 TW TW107115320A patent/TWI787260B/zh active
-
2019
- 2019-10-31 IL IL270326A patent/IL270326B2/en unknown
- 2019-12-02 ZA ZA2019/08006A patent/ZA201908006B/en unknown
-
2021
- 2021-08-13 AU AU2021215274A patent/AU2021215274B2/en active Active
-
2023
- 2023-07-21 JP JP2023119151A patent/JP2023143940A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102444803B1 (ko) | 2022-09-19 |
| RU2760558C9 (ru) | 2022-02-22 |
| KR20210130827A (ko) | 2021-11-01 |
| BR112019022902A2 (pt) | 2020-05-19 |
| JP2020518617A (ja) | 2020-06-25 |
| EP3618819A4 (en) | 2021-01-20 |
| AU2018261654A1 (en) | 2019-11-14 |
| IL270326B2 (en) | 2023-02-01 |
| JP2023143940A (ja) | 2023-10-06 |
| IL270326B (en) | 2022-10-01 |
| MA49464A (fr) | 2020-04-29 |
| IL270326A (ru) | 2018-05-03 |
| AU2021215274B2 (en) | 2022-11-03 |
| WO2018204713A1 (en) | 2018-11-08 |
| ZA201908006B (en) | 2021-04-28 |
| CN110831584B (zh) | 2023-03-10 |
| CN110831584A (zh) | 2020-02-21 |
| TWI787260B (zh) | 2022-12-21 |
| EP3618819A1 (en) | 2020-03-11 |
| TW201842902A (zh) | 2018-12-16 |
| KR20200062078A (ko) | 2020-06-03 |
| RU2019137004A (ru) | 2021-06-04 |
| CA3062452C (en) | 2023-10-24 |
| CA3138116A1 (en) | 2018-11-08 |
| CA3062452A1 (en) | 2018-11-08 |
| RU2760558C2 (ru) | 2021-11-29 |
| AU2021215274A1 (en) | 2021-09-02 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Reissue of patent specification |